Posts

Evotec Announces Up to 800 Job Cuts and Four Site Closures in Horizon Reorganization Phase

on
Evotec announced on March 10 plans to lay off around 800 employees, impacting about one-sixth of its ~4,800-5,000 workforce, as part of the 'Horizon' phase of its reorganization 1 2 3 The company will close four additional sites over the next two years, reducing total sites from 14 to 10; known closures include Framingham (US), Abingdon (UK), Munich (Germany), and Lyon (France) 1 3 5 This follows prior cuts of 600 jobs and site reductions from 19 to 14 between 2024-2025 1 2 3 Measures aim to save 75 million euros by end of 2027, with 100 million euros in restructuring costs from 2026-2028; implementation starts H2 2026, mostly complete by 2027 1 2 CEO Christian Wojczewski stated Horizon transforms the operating model for stronger performance through 2027 and growth toward 2030, targeting >1 billion euros revenue 1 2 3 Sources: 1. https://www.fiercebiotech.com/biotech/evotec-reveals-sweeping-800-person-layoffs-more-site-closures-restructuring-rolls 2. https://ww...

Veeva Systems Acquires Ostro for $100 Million to Boost AI-Driven Pharma Brand Engagement

on

CHARM Therapeutics Raises $80M in Oversubscribed Series B for Next-Gen Menin Inhibitor in AML

on

Recent Advances in Wearable Biosensor Development Programs in 2026

on

Voyager Therapeutics Pauses Alzheimer's APOE Program 8 Months After Unveiling

on

NAMs-Related Presentations at the Upcoming 65th SOT Annual Meeting in San Diego

on

Ipsen Withdraws Tazverik from Market Due to Secondary Malignancy Safety Concerns

on

BMS Receives FDA Approval for Sotyktu in Psoriatic Arthritis Treatment

on

Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer

on

Incyte Receives FDA CRL for Zynyz NSCLC Expansion Due to Issues at Novo Nordisk's Catalent Indiana Facility, Becoming Third Affected Company

on

FDA Approves Leucovorin for Rare Cerebral Folate Deficiency Without New Trial Data

on

Novo Nordisk Receives FDA Warning Letter for Failing to Report Ozempic Safety Signals Including Deaths

on

Capricor Shares Rise as FDA Sets August 2026 Decision Date for Deramiocel in Duchenne Muscular Dystrophy After Prior Rejection

on